Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study

BACKGROUND: Direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) have varying potentials for drug-drug interactions (DDIs). OBJECTIVES: To (1) identify prevalence of potential DDI with glecaprevir-pibrentasvir (GLE-PIB) and sofosbuvir-velpatasvir (SOF-VEL) and (2) describe health care...

Descripción completa

Detalles Bibliográficos
Autores principales: Curry, Michael P, Flamm, Steven L, Milligan, Scott, Tsai, Naoky, Wick, Nicole, Younossi, Zobair, Afdhal, Nezam H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394224/
https://www.ncbi.nlm.nih.gov/pubmed/34105360
http://dx.doi.org/10.18553/jmcp.2021.20550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394224/
https://www.ncbi.nlm.nih.gov/pubmed/34105360
http://dx.doi.org/10.18553/jmcp.2021.20550

Ejemplares similares